Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from HC Wainwright

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $9.00 price objective on the stock.

LCTX has been the topic of several other research reports. B. Riley reduced their price target on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday, March 14th. D. Boral Capital restated a "buy" rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $4.20.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN LCTX opened at $0.95 on Monday. The business has a fifty day moving average price of $0.58 and a 200 day moving average price of $0.61. The company has a market cap of $216.94 million, a P/E ratio of -11.88 and a beta of 1.51. Lineage Cell Therapeutics has a one year low of $0.37 and a one year high of $1.19.

Institutional Trading of Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LCTX. Fort Sheridan Advisors LLC lifted its holdings in Lineage Cell Therapeutics by 71.5% in the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company's stock valued at $28,000 after purchasing an additional 23,000 shares in the last quarter. Atria Wealth Solutions Inc. purchased a new stake in shares of Lineage Cell Therapeutics during the 4th quarter valued at $29,000. HighTower Advisors LLC increased its holdings in shares of Lineage Cell Therapeutics by 49.5% during the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company's stock worth $29,000 after buying an additional 19,100 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of Lineage Cell Therapeutics by 312.2% in the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock worth $44,000 after buying an additional 65,864 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in Lineage Cell Therapeutics during the fourth quarter worth about $46,000. 62.47% of the stock is owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.